Catalyst Funds Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Catalyst Funds Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-630	Closed	-$486K	–	692
2025 Q4	$486K	Sell	630 -1,070	-63%	-$727K	0.11%	179
2025 Q3	$956K	Buy	+1,700	New	+$961K	0.14%	147
2024 Q2	–	Sell	-400	Closed	-$385K	–	1520
2024 Q1	$385K	Buy	+400	New	+$380K	0.11%	163

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Catalyst Funds Management's REGN Position: Q1 2026 in Review

Catalyst Funds Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 630 shares — an estimated $486K sold.

Catalyst Funds Management first reported a position in REGN in Q1 2024 and held it in 3 quarters. The position peaked at $956K in Q3 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Catalyst Funds Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Catalyst Funds Management sold 630 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $486K.
Catalyst Funds Management first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 3 quarters.
Catalyst Funds Management's Regeneron Pharmaceuticals position peaked at $956K in Q3 2025.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.